A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

Clinical trial NCT04030026 · COMPLETED

Trial details

NCT number: NCT04030026
Sponsor: Trevi Therapeutics
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Idiopathic Pulmonary Fibrosis

Start date: 2019-10-29
Primary completion: 2022-05-27
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.